產(chǎn)品目錄

規(guī)格	10mM (in 1mL DMSO) 5mg 10mg 50mg
CAS	1000787-75-6
別名	GS-333126;GS-9190;GS333126;GS9190
化學(xué)名	5-[[6-[2,4-bis(trifluoromethyl)phenyl]pyridazin-3-yl]methyl]-2-(2-fluorophenyl)imidazo[4,5-c]pyridine
分子式	C25H14F7N5
分子量	517.4
溶解度	≥ 24.95 mg/mL in DMSO, ≥ 100 mg/mL in EtOH
儲(chǔ)存條件	Store at -20°C
General tips	For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping Condition	Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request

產(chǎn)品描述：

Tegobuvir (TGV) is a non-nucleoside of HCV RNA replication EC50s of ＜ 16 nM against genotype 1 and ＞100 nM for other genotypes. [1, 2]

Tegobuvir inhibited HCV replication by targeting the NS5B polymerase. The NS5B polymerase is an RNA polymerase which is responsible for HCV replication and is RNA-dependent RNA polymerase.[3, 4] The HCV NS5B contains canonical thumb, finger, and palm subdomains.[3]

Tegobuvir has potent activity against genotypes 1a and 1b HCV in HCV replicons in vitro, and in HCV genotype 1-infected patients and GT 1a EC50 is 17-fold higher than that observed in GT 1b.[5] However, It exhibited reduced activity against GT2a replicons and GT2a infectious virus. Furthermore, the C445F mutation selected by tegobuvir caused a 7.1 fold increase in EC50.[2] Thus, it indicated that the mechanism of tegobuvir is related to HCV NS5B. The data from different mutation of NS5B including C316Y, C445F, and Y452H indicated that the inhibitory effect is due to the interaction with the hairpin in the thumb subdomain.[2] But, The mechanism of TGV still has not been clearly defined. TGV does not have any inhibition effect on NS5B enzymatic activity with recombinant NS5B proteins.[5] A decrease in antiviral potency of TGV was observed when a CYP1A inhibitor was combined used in antiviral assays. It demonstrated that TGV binds to the NS5B polymerase after undergoing a multistep metabolic activation pathway.[5] The activity of TGV also is related to the specific glutathione adducts.[5] Besides the sub-type differences, TGV also is less potent against the GT 1b replicon in the HeLa cell line with EC50＞10 M.

When individual patients treated only with tegobuvir with 8 days, it demonstrated median reductions of 1.5 log10 IU/mL in HCV RNA. But, rates of RVR (HCV RNA< 25 IU/mL at week 4) was enhanced when treated with Peg-IFN and RBV at the same time.[5]

特別提醒：

1. 本產(chǎn)品僅供科研使用。請(qǐng)勿用于醫(yī)藥、臨床診斷或治療，食品及化妝品等用途。請(qǐng)勿存放于普通住宅區(qū)。

2. 為了您的安全和健康，請(qǐng)穿好實(shí)驗(yàn)服并佩戴一次性手套和口罩操作。

原創(chuàng)作者：上海莼試生物技術(shù)有限公司

在線咨詢

留言注意事項(xiàng)：

1.遵守中華人民共和國(guó)有關(guān)法律、法規(guī)，尊重網(wǎng)上道德，承擔(dān)一切因您的行為而直接或間接引起的法律責(zé)任。

2.請(qǐng)您真實(shí)的反映產(chǎn)品的情況,不要捏造、誣蔑、造謠。如對(duì)產(chǎn)品有任何疑問(wèn),也可以留言咨詢。

3.未經(jīng)本站同意，任何人不得利用本留言簿發(fā)布個(gè)人或團(tuán)體的具有廣告性質(zhì)的信息或類似言論。

您感興趣的產(chǎn)品*
您的單位*
聯(lián)系人*
聯(lián)系電話*
詳細(xì)地址*
常用郵箱*
請(qǐng)輸入您對(duì)我們的意見(jiàn)或建議*
驗(yàn)證碼*